ALTIMMUNE, INC. Business Combination, Contingent Consideration, Liability
ALTIMMUNE, INC. (ALT) had Business Combination, Contingent Consideration, Liability of $0 as of 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Balance Sheet › Liabilities
us-gaap:BusinessCombinationContingentConsiderationLiability · last filed 2023-05-11
- 2023-03-31: Business Combination, Contingent Consideration, Liability $0.00.
- 2022-12-31: Business Combination, Contingent Consideration, Liability $0.00.
- 2022-03-31: Business Combination, Contingent Consideration, Liability $4.31M.
- 2021-12-31: Business Combination, Contingent Consideration, Liability $6.09M.
| Period end | Business Combination, Contingent Consideration, Liability |
|---|---|
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 |
| 2022-12-31 | $0.00 10-Q · filed 2023-05-11 |
| 2022-03-31 | $4.31M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $6.09M 10-K · filed 2023-02-28 |
| 2021-09-30 | $6.95M 10-Q · filed 2022-11-10 |
| 2021-06-30 | $5.27M 10-Q · filed 2022-08-11 |
| 2021-03-31 | $6.27M 10-Q · filed 2022-05-12 |
| 2020-12-31 | $5.39M 10-K · filed 2023-02-28 |
| 2020-09-30 | $25.07M 10-Q · filed 2021-11-09 |
| 2020-06-30 | $16.39M 10-Q · filed 2021-08-10 |
| 2020-03-31 | $4.50M 10-Q · filed 2021-05-17 |
| 2019-12-31 | $2.75M 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |